{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:53:11Z","timestamp":1777463591997,"version":"3.51.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1124\/mol.113.090357","type":"journal-article","created":{"date-parts":[[2013,11,16]],"date-time":"2013-11-16T03:39:09Z","timestamp":1384573149000},"page":"269-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Potent Antimycobacterial Activity of the Pyridoxal Isonicotinoyl Hydrazone Analog 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone: A Lipophilic Transport Vehicle for Isonicotinic Acid Hydrazide"],"prefix":"10.1016","volume":"85","author":[{"given":"Samantha","family":"Ellis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danuta S.","family":"Kalinowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Leotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.H.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Jelfs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitali","family":"Sintchenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Des R.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Triccas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/mol.113.090357_bib1","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1128\/AAC.00830-09","article-title":"Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis","volume":"53","author":"Almeida","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/mol.113.090357_bib2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.1840150323","article-title":"Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture","volume":"15","author":"Baker","year":"1992","journal-title":"Hepatology"},{"key":"10.1124\/mol.113.090357_bib3","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S0022-2143(99)90173-7","article-title":"Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs","volume":"134","author":"Becker","year":"1999","journal-title":"J Lab Clin Med"},{"key":"10.1124\/mol.113.090357_bib4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s007750100258","article-title":"Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy","volume":"6","author":"Bernhardt","year":"2001","journal-title":"J Biol Inorg Chem"},{"key":"10.1124\/mol.113.090357_bib5","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1039\/b704102k","article-title":"Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity","volume":"30","author":"Bernhardt","year":"2007","journal-title":"Dalton Trans"},{"key":"10.1124\/mol.113.090357_bib6","first-page":"71","article-title":"Molecular structures: perception, autocorrelation descriptor and SAR studies. System of atomic contributions for the calculation of the n-octanol\/water partition coefficients","volume":"19","author":"Broto","year":"1984","journal-title":"Eur J Med Chem"},{"key":"10.1124\/mol.113.090357_bib7","first-page":"2","article-title":"Iron overload and tuberculosis: a case for iron chelation therapy","volume":"9","author":"Cronje","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1124\/mol.113.090357_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.femsim.2005.02.007","article-title":"Iron and iron chelating agents modulate Mycobacterium tuberculosis growth and monocyte-macrophage viability and effector functions","volume":"45","author":"Cronj\u00e9","year":"2005","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1124\/mol.113.090357_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00002030-199902250-00010","article-title":"Bone marrow macrophage iron grade and survival of HIV-seropositive patients","volume":"13","author":"de Mony\u00e9","year":"1999","journal-title":"AIDS"},{"key":"10.1124\/mol.113.090357_bib10","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.virol.2007.06.011","article-title":"Iron chelators ICL670 and 311 inhibit HIV-1 transcription","volume":"367","author":"Debebe","year":"2007","journal-title":"Virology"},{"key":"10.1124\/mol.113.090357_bib11","first-page":"77","article-title":"Role of iron in the pathogenesis of Mycobacterium avium infection in mice","volume":"87","author":"Dhople","year":"1996","journal-title":"Microbios"},{"key":"10.1124\/mol.113.090357_bib12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.mimet.2011.11.006","article-title":"Evaluation of nitrate reduction assay, resazurin microtiter assay and microscopic observation drug susceptibility assay for first line antitubercular drug susceptibility testing of clinical isolates of M. tuberculosis","volume":"88","author":"Dixit","year":"2012","journal-title":"J Microbiol Methods"},{"key":"10.1124\/mol.113.090357_bib13","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/j.1462-5822.2009.01335.x","article-title":"Mycobacterial survival strategies in the phagosome: defence against host stresses","volume":"11","author":"Ehrt","year":"2009","journal-title":"Cell Microbiol"},{"key":"10.1124\/mol.113.090357_bib14","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1128\/AAC.42.3.712","article-title":"Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice","volume":"42","author":"Fattorini","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/mol.113.090357_bib15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1083\/jcb.89.3.645","article-title":"Temporal changes of lysosome and phagosome pH during phagolysosome formation in macrophages: studies by fluorescence spectroscopy","volume":"89","author":"Geisow","year":"1981","journal-title":"J Cell Biol"},{"key":"10.1124\/mol.113.090357_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1021\/ci00053a005","article-title":"Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions","volume":"27","author":"Ghose","year":"1987","journal-title":"J Chem Inf Comput Sci"},{"key":"10.1124\/mol.113.090357_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1386-6532(00)00135-9","article-title":"Role of iron in experimental Mycobacterium avium infection","volume":"20","author":"Gomes","year":"2001","journal-title":"J Clin Virol"},{"key":"10.1124\/mol.113.090357_bib18","doi-asserted-by":"crossref","first-page":"e29631","DOI":"10.1371\/journal.pone.0029631","article-title":"Vitamins A & D inhibit the growth of mycobacteria in radiometric culture","volume":"7","author":"Greenstein","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1124\/mol.113.090357_bib19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0304-4165(00)00115-X","article-title":"The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by ferric iron plus ascorbate","volume":"1523","author":"Hermes-Lima","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/mol.113.090357_bib20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1021\/jm7012562","article-title":"Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series","volume":"51","author":"Kalinowski","year":"2008","journal-title":"J Med Chem"},{"key":"10.1124\/mol.113.090357_bib21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.bbagen.2005.12.026","article-title":"Catalase-peroxidase of Mycobacterium bovis BCG converts isoniazid to isonicotinamide, but not to isonicotinic acid: differentiation parameter between enzymes of Mycobacterium bovis BCG and Mycobacterium tuberculosis","volume":"1760","author":"Kang","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/mol.113.090357_bib22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/AAC.38.2.170","article-title":"In vivo activity of paromomycin against susceptible and multidrug-resistant Mycobacterium tuberculosis and M. avium complex strains","volume":"38","author":"Kanyok","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/mol.113.090357_bib23","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1124\/mol.111.073627","article-title":"Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer","volume":"80","author":"Kovacevic","year":"2011","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.113.090357_bib24","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/jssc.200500077","article-title":"Development of high-performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to an in vivo study","volume":"28","author":"Kovar\u00edkov\u00e1","year":"2005","journal-title":"J Sep Sci"},{"key":"10.1124\/mol.113.090357_bib25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1054\/tube.2002.0335","article-title":"Optimization of electroporation conditions for Mycobacterium avium","volume":"82","author":"Lee","year":"2002","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1124\/mol.113.090357_bib26","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1182\/blood-2002-08-2382","article-title":"Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells","volume":"101","author":"Link","year":"2003","journal-title":"Blood"},{"key":"10.1124\/mol.113.090357_bib27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1386-6532(00)00136-0","article-title":"Iron and Mycobacterium tuberculosis infection","volume":"20","author":"Lounis","year":"2001","journal-title":"J Clin Virol"},{"key":"10.1124\/mol.113.090357_bib28","doi-asserted-by":"crossref","first-page":"7230","DOI":"10.1021\/jm300768u","article-title":"Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo","volume":"55","author":"Lovejoy","year":"2012","journal-title":"J Med Chem"},{"key":"10.1124\/mol.113.090357_bib29","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1128\/AAC.48.12.4550-4555.2004","article-title":"Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis","volume":"48","author":"Nikonenko","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/mol.113.090357_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1086\/380413","article-title":"Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing bacille Calmette-Gu\u00e9rin vaccine","volume":"189","author":"Pinto","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1124\/mol.113.090357_bib31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0014-5793(79)80111-8","article-title":"Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent","volume":"97","author":"Ponka","year":"1979","journal-title":"FEBS Lett"},{"key":"10.1124\/mol.113.090357_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/jac\/dkf104","article-title":"Iron chelators as antimalarial agents: in vitro activity of dicatecholate against Plasmodium falciparum","volume":"50","author":"Pradines","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/mol.113.090357_bib33","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1128\/AAC.35.6.1035","article-title":"Isoniazid inhibition of mycolic acid synthesis by cell extracts of sensitive and resistant strains of Mycobacterium aurum","volume":"35","author":"Qu\u00e9mard","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/mol.113.090357_bib34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF01129203","article-title":"Pyridoxal isonicotinoyl hydrazone and analogues. Study of their stability in acidic, neutral and basic aqueous solutions by ultraviolet-visible spectrophotometry","volume":"2","author":"Richardson","year":"1989","journal-title":"Biol Met"},{"key":"10.1124\/mol.113.090357_bib35","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.bbagen.2008.04.003","article-title":"Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents","volume":"1790","author":"Richardson","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/mol.113.090357_bib36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0925-4439(01)00041-2","article-title":"Development of potential iron chelators for the treatment of Friedreich\u2019s ataxia: ligands that mobilize mitochondrial iron","volume":"1536","author":"Richardson","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/mol.113.090357_bib37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0022-2143(98)90049-X","article-title":"Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs","volume":"132","author":"Richardson","year":"1998","journal-title":"J Lab Clin Med"},{"key":"10.1124\/mol.113.090357_bib38","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0022-2143(98)90180-9","article-title":"Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease","volume":"131","author":"Richardson","year":"1998","journal-title":"J Lab Clin Med"},{"key":"10.1124\/mol.113.090357_bib39","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1182\/blood.V86.11.4295.bloodjournal86114295","article-title":"The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents","volume":"86","author":"Richardson","year":"1995","journal-title":"Blood"},{"key":"10.1124\/mol.113.090357_bib40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0020-1693(00)80471-5","article-title":"Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part I. Ionisation characteristics of the ligands and their relevance to biological properties","volume":"170","author":"Richardson","year":"1990","journal-title":"Inorg Chim Acta"},{"key":"10.1124\/mol.113.090357_bib41","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1046\/j.1440-1711.2002.01121.x","article-title":"Characterization of immune responses during infection with Mycobacterium avium strains 100, 101 and the recently sequenced 104","volume":"80","author":"Saunders","year":"2002","journal-title":"Immunol Cell Biol"},{"key":"10.1124\/mol.113.090357_bib42","doi-asserted-by":"crossref","unstructured":"Sinclair D, Abba K, Grobler L, Sudarsanam TD (2011) Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst Rev (11):CD006086.","DOI":"10.1002\/14651858.CD006086.pub3"},{"key":"10.1124\/mol.113.090357_bib43","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1128\/IAI.67.9.4586-4593.1999","article-title":"Assessment of immunity to mycobacterial infection with luciferase reporter constructs","volume":"67","author":"Snewin","year":"1999","journal-title":"Infect Immun"},{"key":"10.1124\/mol.113.090357_bib44","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3109\/01480549109011641","article-title":"Toxicological study of pyridoxal isonicotinoyl hydrazone: acute and subchronic toxicity","volume":"14","author":"Sookvanichsilp","year":"1991","journal-title":"Drug Chem Toxicol"},{"key":"10.1124\/mol.113.090357_bib45","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijantimicag.2006.11.009","article-title":"Necrosis of host cells and survival of pathogens following iron overload in an in vitro model of co-infection with human immunodeficiency virus (HIV) and Mycobacterium tuberculosis","volume":"29","author":"Traor\u00e9","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1124\/mol.113.090357_bib46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.micro.61.111606.122346","article-title":"The mechanism of isoniazid killing: clarity through the scope of genetics","volume":"61","author":"Vilch\u00e8ze","year":"2007","journal-title":"Annu Rev Microbiol"},{"key":"10.1124\/mol.113.090357_bib47","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1021\/ci00063a006","volume":"29","author":"Viswanadhan","year":"1989","journal-title":"J Chem Inf Comput Sci"},{"key":"10.1124\/mol.113.090357_bib48","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1357-2725(03)00248-6","article-title":"Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites","volume":"36","author":"Walcourt","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1124\/mol.113.090357_bib49","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1139\/y83-073","article-title":"Isoniazid-induced hepatic steatosis in rabbits: an explanation for susceptibility and its antagonism by pyridoxine hydrochloride","volume":"61","author":"Whitehouse","year":"1983","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1124\/mol.113.090357_bib50","doi-asserted-by":"crossref","first-page":"14901","DOI":"10.1073\/pnas.0604979103","article-title":"A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics","volume":"103","author":"Whitnall","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.113.090357_bib51","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2004.09.001","article-title":"PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice","volume":"1739","author":"Wong","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/mol.113.090357_bib52","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.tim.2013.05.002","article-title":"Rising to the challenge: new therapies for tuberculosis","volume":"21","author":"Wong","year":"2013","journal-title":"Trends Microbiol"},{"key":"10.1124\/mol.113.090357_bib53","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1021\/jm900552r","article-title":"Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors","volume":"52","author":"Yu","year":"2009","journal-title":"J Med Chem"},{"key":"10.1124\/mol.113.090357_bib54","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1158\/1078-0432.CCR-06-1954","article-title":"Chelators at the cancer coalface: desferrioxamine to Triapine and beyond","volume":"12","author":"Yu","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24038689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24038689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.113.090357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:19:00Z","timestamp":1739963940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24038689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0026895X24038689"],"URL":"https:\/\/doi.org\/10.1124\/mol.113.090357","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potent Antimycobacterial Activity of the Pyridoxal Isonicotinoyl Hydrazone Analog 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone: A Lipophilic Transport Vehicle for Isonicotinic Acid Hydrazide","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.113.090357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}